Risk of Retinal Vein Occlusion between Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Chien‐Hsiang Weng (ORCID: https://orcid.org/0000-0002-0794-1263)
- Yi‐Jing Sheen (ORCID: https://orcid.org/0000-0001-6482-7347)
- Ssu‐Yu Pan (ORCID: https://orcid.org/0009-0007-4620-1755)
- Jun‐Fu Lin (ORCID: https://orcid.org/0009-0006-5287-7893)
- I‐Jong Wang (ORCID: https://orcid.org/0000-0002-3045-0614)
- Peng‐Tai Tien (ORCID: https://orcid.org/0000-0002-9099-3151)
- Chien‐Chih Chou (ORCID: https://orcid.org/0000-0003-3332-0900)
- Hui‐Ju Lin (ORCID: https://orcid.org/0000-0003-2606-8540)
- Ching‐Heng Lin (ORCID: https://orcid.org/0000-0002-2450-6108)
- Shang-Feng Tsai
Institutions
- Fu Jen Catholic University (TW)
- Rhode Island Department of Health (US)
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- Tunghai University (TW)
- China Medical University (TW)
- Brown University (US)
- Taichung Veterans General Hospital (TW)
- China Medical University Hospital (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1016/j.xops.2025.100734
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Novo Nordisk
- Taichung Veterans General Hospital